Bruton's tyrosine kinase

May 15, 2018

Oncternal Opens its CIRLL Study, a Combination Trial of Cirmtuzumab with Ibrutinib in B-Cell Malignancies

Mar 07, 2018

Merck KGaA, Darmstadt, Germany, Announces Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis

Dec 01, 2017

Xynomic Pharma Initiates Ph 1/2 Trial Combining Abexinostat with Ibrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) and Mantle Cell Lymphoma (r/r MCL)

Jun 24, 2017

European Hematology Association: Multicenter Open-label Phase 2 Study of ibrutinib in Chronic Graft Versus Host Disease (cGVHD) After Failure of Corticosteroids

Jun 05, 2017

Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated with Ibrutinib, Including Those with High-Risk Disease, with Up to Four Years of Follow-Up